MAFD9
MCID: MJR024
MIFTS: 41

Major Affective Disorder 9 (MAFD9)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 9

MalaCards integrated aliases for Major Affective Disorder 9:

Name: Major Affective Disorder 9 56 13 71
Major Affective Disorder-9, Susceptibility to 56
Bipolar Affective Disorder 56
Major Affective Disorder-9 56
Bipolar Disorder 71
Mafd9 56

Classifications:



External Ids:

OMIM 56 612372
MedGen 41 C2700440
UMLS 71 C0005586 C2700440

Summaries for Major Affective Disorder 9

MalaCards based summary : Major Affective Disorder 9, also known as major affective disorder-9, susceptibility to, is related to major affective disorder 1 and bipolar disorder. An important gene associated with Major Affective Disorder 9 is MAFD9 (Major Affective Disorder-9, Susceptibility To). The drugs Eleuthero and Reboxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and testes.

More information from OMIM: 612372

Related Diseases for Major Affective Disorder 9

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 major affective disorder 1 12.5
2 bipolar disorder 12.3
3 major affective disorder 5 12.0
4 major affective disorder 6 12.0
5 major affective disorder 2 12.0
6 major affective disorder 8 11.9
7 major affective disorder 3 11.7
8 major affective disorder 4 11.7
9 major affective disorder 7 11.7
10 mood disorder 10.7
11 endogenous depression 10.5
12 schizophrenia 10.5
13 depression 10.5
14 mental depression 10.5
15 bipolar i disorder 10.4
16 major depressive disorder 10.4
17 personality disorder 10.3
18 psychotic disorder 10.3
19 schizoaffective disorder 10.3
20 alcohol dependence 10.3
21 tardive dyskinesia 10.3
22 obsessive-compulsive disorder 10.3
23 substance abuse 10.2
24 hypothyroidism 10.2
25 attention deficit-hyperactivity disorder 10.2
26 cyclothymic disorder 10.2
27 huntington disease 10.1
28 mental health wellness 1 10.1
29 mental health wellness 2 10.1
30 borderline personality disorder 10.1
31 severe combined immunodeficiency 10.1
32 multiple sclerosis 10.1
33 thalassemia 10.1
34 hydrocephalus 10.1
35 avoidant personality disorder 10.1
36 adenoma 10.1
37 head injury 10.1
38 schizophrenia 1 10.0
39 frontotemporal dementia 10.0
40 anxiety 10.0
41 alacrima, achalasia, and mental retardation syndrome 10.0
42 exanthem 10.0
43 physical disorder 10.0
44 dementia 10.0
45 alcohol use disorder 10.0
46 movement disease 10.0
47 panic disorder 10.0
48 hyperthyroidism 10.0
49 learning disability 10.0
50 substance dependence 10.0

Comorbidity relations with Major Affective Disorder 9 via Phenotypic Disease Network (PDN):


Acute Cystitis Bipolar Disorder
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Major Affective Disorder 9:



Diseases related to Major Affective Disorder 9

Symptoms & Phenotypes for Major Affective Disorder 9

Clinical features from OMIM:

612372

Drugs & Therapeutics for Major Affective Disorder 9

Drugs for Major Affective Disorder 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 424)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Reboxetine Approved, Experimental Phase 4 98769-81-4, 71620-89-8 123628 65856
3
Oxcarbazepine Approved Phase 4 28721-07-5 34312
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Galantamine Approved Phase 4 357-70-0 9651
6
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 497540 5095
7
Memantine Approved, Investigational Phase 4 19982-08-2 4054
8
Topiramate Approved Phase 4 97240-79-4 5284627
9
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
10
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
11
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
12
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
13
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
14
Levetiracetam Approved Phase 4 102767-28-2 441341
15
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
16
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
17
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
18
Cycloserine Approved Phase 4 68-41-7 401 6234
19
Norepinephrine Approved Phase 4 51-41-2 439260
20
Sertraline Approved Phase 4 79617-96-2 68617
21
Nortriptyline Approved Phase 4 72-69-5 4543
22
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
23
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
24
Histamine Approved, Investigational Phase 4 51-45-6 774
25
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
26
Iloperidone Approved Phase 4 133454-47-4 71360
27
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
28
Methohexital Approved Phase 4 151-83-7 9034
29
Dipyridamole Approved Phase 4 58-32-2 3108
30
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
31
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
32
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
33
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
34
Lorazepam Approved Phase 4 846-49-1 3958
35
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
36
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
37
Loxapine Approved Phase 4 1977-10-2 3964
38
Metformin Approved Phase 4 657-24-9 14219 4091
39
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
40
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 5826 3007
41
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
42
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
43
Acetaminophen Approved Phase 4 103-90-2 1983
44
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
45
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
46
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
47
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
48
Racepinephrine Approved Phase 4 329-65-7 838
49
Ondansetron Approved Phase 4 99614-02-5 4595
50
Simvastatin Approved Phase 4 79902-63-9 54454

Interventional clinical trials:

(show top 50) (show all 1542)
# Name Status NCT ID Phase Drugs
1 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
2 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
3 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
4 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
5 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
6 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
7 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
8 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
9 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
10 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
11 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
12 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
13 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
14 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
15 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
16 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in PCOS Patients. Unknown status NCT01246310 Phase 4
17 Integrated Smoking Cessation Treatment for Smokers With Serious Mental Illness Unknown status NCT02845440 Phase 4
18 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
19 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
20 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
21 Comparison of Propofol Target-Controlled Infusion Anesthesia and Bolus Injection in Electroconvulsive Therapy: A Randomized Controlled Trial Completed NCT03863925 Phase 4
22 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
23 A Multi-center, Randomized, Double-blind, Parallel Group, Placebo-controlled 52 Weeks Clinical Trial to Evaluate Efficacy and Safety of Oxcarbazepine p.o.(300-1200 mg/Day) as Adjuvant Therapy in the Bipolar Disorder I or II Treatment Completed NCT00154323 Phase 4 Oxcarbazepine
24 A Randomized, Open Label Trial of Olanzapine Versus Lithium in the Treatment of Acute Depression in Patients With Bipolar II or Bipolar Not Otherwise Specified. Completed NCT02287259 Phase 4 olanzapine;lithium
25 An Open-Label Extension Study to Assess the Safety of Lamotrigine in Subjects With Bipolar Disorder, Who Are in Remission Following a Manic/Hypomanic Index Episode or a Depressive Index Episode. Completed NCT00360126 Phase 4 lamotrigine
26 Lamictal As Add on Treatment in Mixed States of Bipolar Disorder Completed NCT00223509 Phase 4 Lamotrigine
27 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
28 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
29 A 52-week, Open-label Extension Study to Evaluate the Safety and Tolerability of Licarbazepine in the Treatment of Manic Episodes of Bipolar I Disorder Completed NCT00139594 Phase 4 licarbazepine
30 Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder Completed NCT00050206 Phase 4 Olanzapine;Placebo
31 A Randomized, Double-Blind, Placebo Controlled Study Of Quetiapine SR (QTP) As Adjunctive Treatment In Mixed States (MS) Of Bipolar Disorder Completed NCT01195363 Phase 4 quetiapine SR;quetiapine sr placebo
32 Cognitive Enhancement in Bipolar Disorder Completed NCT00597896 Phase 4 pramipexole
33 Aripiprazole in Late Life Bipolar Disorder Completed NCT00194038 Phase 4 Aripiprazole
34 A Randomized, Double-blind, Placebo-controlled Study of the Efficacy of Ropinirole in the Treatment of Depression in Bipolar Disorder Completed NCT00314821 Phase 4 ropinirole
35 18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder Completed NCT03902613 Phase 4 Lurasidone
36 Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder Completed NCT00472641 Phase 4 Ziprasidone/Geodon
37 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
38 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
39 Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder Completed NCT00190892 Phase 4 olanzapine;carbamazepine
40 Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder, Manic or Mixed Completed NCT00034580 Phase 4 olanzapine;risperidone
41 Olanzapine/Fluoxetine Combination Versus Lamotrigine in the Treatment of Bipolar I Depression Completed NCT00485771 Phase 4 Olanzapine;Fluoxetine;Lamotrigine
42 Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study Completed NCT00477373 Phase 4 depakine chrono
43 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
44 A Phase IV STudy of the Effectiveness of Quetiapine Extended Release 600mg Once a Day to Control the Symptoms of Manic Phase of Bipolar Disorder. Completed NCT00521365 Phase 4 Quetiapine 600mg
45 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4 Divalproex ER
46 Tranylcypromine Treatment of Bipolar Depression Completed NCT01430455 Phase 4 Tranylcypromine
47 A Double-Blind, Randomized, Placebo-Controlled Trial of Ramelteon for the Treatment of Insomnia and Mood Stability in Patients With Euthymic Bipolar Disorder. Completed NCT00552760 Phase 4 Ramelteon;Placebo
48 Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder Completed NCT00094549 Phase 4 olanzapine;divalproex sodium;placebo
49 A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder Completed NCT00195845 Phase 4 Galantamine;Placebos
50 A Double Blind, Randomized, Placebo Controlled Trial of Aripiprazole Plus Valproate in the Short-Term and Long-Term Treatment of Bipolar Disorder Completed NCT00484471 Phase 4 aripiprazole;valproate;placebo

Search NIH Clinical Center for Major Affective Disorder 9

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 9

Anatomical Context for Major Affective Disorder 9

MalaCards organs/tissues related to Major Affective Disorder 9:

40
Brain, Cortex, Testes, Prefrontal Cortex, Amygdala, Thyroid, Cingulate Cortex

Publications for Major Affective Disorder 9

Articles related to Major Affective Disorder 9:

(show top 50) (show all 25788)
# Title Authors PMID Year
1
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 56 61
18711365 2008
2
Neuropsychological development in the child and adolescent offspring of patients diagnosed with schizophrenia or bipolar disorder: A two-year follow-up comparative study. 61
32454164 2020
3
Common variants in FAN1, located in 15q13.3, confer risk for schizophrenia and bipolar disorder in Han Chinese. 61
32450113 2020
4
The associations between illness perceptions and social rhythm stability on mood symptoms among patients with bipolar disorder. 61
32560948 2020
5
Cognitive remediation for the treatment of neuropsychological disturbances in subjects with euthymic bipolar disorder: findings from a controlled study. 61
32560956 2020
6
Eotaxin-1/CCL11 correlates with left superior temporal gyrus in bipolar disorder: A preliminary report suggesting accelerated brain aging. 61
32560958 2020
7
Familial severe psychiatric history in bipolar disorder and correlation with disease severity and treatment response. 61
32421593 2020
8
Self-Destigmatization Process? Experiences of Persons Living with Bipolar Disorder: A Qualitative Study. 61
32266548 2020
9
Neuro-transcriptomic signatures for mood disorder morbidity and suicide mortality. 61
32485434 2020
10
Sleep and sleep treatments in bipolar disorder. 61
32203912 2020
11
An update on sleep in bipolar disorders: presentation, comorbidities, temporal relationships and treatment. 61
31521023 2020
12
Suicide mortality after discharge from inpatient care for bipolar disorder: A 14-year Swedish national registry study. 61
32450359 2020
13
Linguistic analysis of autobiographical narratives in unipolar and bipolar mood disorders in light of multiple code theory. 61
32421609 2020
14
Depression with and without a history of psychotic symptoms in the general population: sociodemographic and clinical characteristics. 61
32423890 2020
15
The HPA axis dysregulation in severe mental illness: Can we shift the blame to gut microbiota? 61
32335265 2020
16
Efficacy of intensive short-term dynamic psychotherapy in mood disorders: A critical review. 61
32560931 2020
17
Rate of diagnostic conversion to bipolar disorder in adults with unipolar depression and psychopharmacological treatment in the republic of Korea: A nationwide register-based study. 61
32421610 2020
18
The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor. 61
32470749 2020
19
Na+/K+-ATPase and lipid peroxidation in forebrain cortex and hippocampus of sleep-deprived rats treated with therapeutic lithium concentration for different periods of time. 61
32360816 2020
20
Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. 61
32563306 2020
21
Perinatal biomarkers implying 'Developmental Origins of Health and Disease' consequences in intrauterine growth restriction. 61
31577039 2020
22
Cognitive impairment in individuals with bipolar disorder with and without comorbid alcohol and/or cocaine use disorders. 61
32553378 2020
23
Altered functional connectivity of right inferior frontal gyrus subregions in bipolar disorder: a resting state fMRI study. 61
32379621 2020
24
The development of a theoretically derived measure exploring extreme appraisals of sleep in bipolar disorder: a Delphi study with professionals. 61
32157985 2020
25
Glial and neuronal markers in bipolar disorder: A meta-analysis testing S100B and NSE peripheral blood levels. 61
32171903 2020
26
Investigation of structure-function correlation among the young offspring of patients with bipolar disorder. 61
32464339 2020
27
Euthymic bipolar disorder patients and EEG microstates: a neural signature of their abnormal self experience? 61
32553374 2020
28
Toward prevention of bipolar disorder in at-risk children: Potential strategies ahead of the data. 61
32553395 2020
29
Reply to comments on the risk of incident bipolar disorder in polycystic ovary syndrome. 61
32379607 2020
30
Image qualities and mood variability: Evaluating the utility of an imagery survey for bipolar disorder. 61
32379623 2020
31
The role of CACNA1C gene and childhood trauma interaction on bipolar disorder. 61
32169562 2020
32
From apathy to addiction: Insights from neurology and psychiatry. 61
32171904 2020
33
Emotional body language: Social cognition deficits in bipolar disorder. 61
32553363 2020
34
Bivariate genome-wide association analyses of the broad depression phenotype combined with major depressive disorder, bipolar disorder or schizophrenia reveal eight novel genetic loci for depression. 61
30626913 2020
35
Dysregulation of synaptic pruning as a possible link between intestinal microbiota dysbiosis and neuropsychiatric disorders. 61
32239720 2020
36
Screening for alcohol use disorder among individuals with comorbid psychiatric disorders: Diagnostic accuracy in a sample of young Swiss men. 61
32135396 2020
37
Neurobehavioral changes arising from early life dopamine signaling perturbations. 61
32325191 2020
38
Risk of Delayed Discharge and Reoperation of Gastric Bypass Patients with Psychiatric Comorbidity-a Nationwide Cohort Study. 61
32152840 2020
39
Derivation of poly-methylomic profile scores for schizophrenia. 61
32194204 2020
40
Bipolar Disorder and Psychosis in Autism. 61
32471593 2020
41
Predictive factors of functional outcome in patients with bipolar I disorder: a five-year follow-up. 61
32553365 2020
42
Attitudes towards suicide and risk factors for suicide attempts among university students in South Korea. 61
32379610 2020
43
Unified and disease specific alterations to brain structure in patients across six categories of mental disorders who experience own-thought auditory verbal hallucinations: A pilot study. 61
32298780 2020
44
Electroconvulsive therapy decreases striatal dopamine transporter binding in patients with depression: A positron emission tomography study with [18F]FE-PE2I. 61
32464340 2020
45
Effect of interaction between a specific subtype of child abuse and the FKBP5 rs1360780 SNP on DNA methylation among patients with bipolar disorder. 61
32553385 2020
46
Brain structural correlates of familial risk for mental illness: a meta-analysis of voxel-based morphometry studies in relatives of patients with psychotic or mood disorders. 61
32353861 2020
47
Abnormal expression of colony stimulating factor 1 receptor (CSF1R) and transcription factor PU.1 (SPI1) in the spleen from patients with major psychiatric disorders: A role of brain-spleen axis. 61
32379601 2020
48
Glycogen synthase kinase-3: The missing link to aberrant circuit function in disorders of cognitive dysfunction? 61
32305493 2020
49
Hypothalamic-pituitary-adrenal axis-related genes and cognition in major mood disorders and schizophrenia: a systematic review. 61
32197928 2020
50
Childhood abuse and intimate partner violence among women with mood disorders. 61
32553375 2020

Variations for Major Affective Disorder 9

Expression for Major Affective Disorder 9

Search GEO for disease gene expression data for Major Affective Disorder 9.

Pathways for Major Affective Disorder 9

GO Terms for Major Affective Disorder 9

Sources for Major Affective Disorder 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....